Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Go back to Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 6.18 -0.01 (0.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.19 | 52 Week High | $45.34 | |||
| Open | $6.12 | 52 Week Low | $15.92 | |||
| Day High | $6.24 | P/E | 2.65 | |||
| Day Low | $6.06 | EPS | $2.33 | |||
| Volume | 734,442 | |||||
